Clinical trial
A Phase 1 First-In-Human Study Evaluating Safety, Pharmacokinetics, and Efficacy of ABBV 291 in Non-Hodgkin's Lymphoma
NCT06667687 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1 First-In-Human Study Evaluating Safety, Pharmacokinetics, and Efficacy of ABBV 291 in Non-Hodgkin's Lymphoma
- Lead sponsor
- AbbVie
- Phase
- Phase 1
- Overall status
- Active, not recruiting
- Start date
- January 16, 2025
- Completion date
- November 30, 2031
- Enrollment
- 21 (actual)
- Sites
- 14
Conditions
As the registry lists them; a condition with its own page is linked.
non-hodgkin's lymphoma